Skip to main content

OxyContin pills at a pharmacy in Provo, Utah, on April 25, 2017.George Frey/Reuters

OxyContin maker Purdue Pharma LP reached a countrywide settlement Thursday over its role in the opioid crisis, with the Sackler family members who own the company boosting their cash contribution to as much as US$6-billion.

The deal follows an earlier settlement that had been appealed by eight states and the District of Columbia. They agreed to sign on after the Sacklers kicked in more cash and accepted other terms. In exchange, the family would be protected from civil lawsuits.

In all, the plan could be worth more than US$10-billion over time. It calls for members of the Sackler family to give up control of the Stamford, Conn.-based company so it can be turned into a new entity with profits used to fight the crisis. The deal would not shield members of the family from criminal charges, although there’s no indication any are forthcoming.

Sackler family members have not unequivocally offered an apology but issued a statement of regret about the toll of OxyContin, its signature painkiller that users learned could be manipulated to produce quick highs. Purdue Pharma had promoted its use for a broad range of pain issues for which doctors previously had shied away from prescribing opioids.

“While the families have acted lawfully in all respects, they sincerely regret that OxyContin, a prescription medicine that continues to help people suffering from chronic pain, unexpectedly became part of an opioid crisis that has brought grief and loss to far too many families and communities,” the statement from the Sackler family said.

Under the settlement, victims also are to have a forum, by video conference, in court to address some of the Sacklers. That’s something they have not been able to do previously in a public setting.

The settlement is outlined in a report filed in U.S. Bankruptcy Court in White Plains, N.Y., and must be approved by the judge. It was hammered out with attorneys-general from the eight states and D.C. who had opposed the earlier one, arguing that it did not properly hold Sackler family members accountable.

For Suzanne Domagala, of Millville, Del., even a modest payout to victims from the Sackler family is important, though she is still upset that the family is getting protection from lawsuits.

Ms. Domagala’s son Zach, a Marine Corps reservist, became addicted after injuring his shoulder during boot camp. When he died in 2017, she said, she didn’t have the money to bury him, and it took a few years before she could afford a headstone.

“That’s why when you’re looking at the costs of these things, money is such a trivial thing,” she said, “but it’s the only way to exact any justice.”

Ed Bisch, whose 18-year-old son died of an overdose 20 years ago, is glad states pushed Sackler family members to pay more. Still, he called the settlement “a horrible deal” because so many parents who buried loved ones won’t see money – and the Sacklers will still be wealthy and free.

“Guess what? They still made billions and billions of dollars,” said Mr. Bisch, of Westampton, N.J. “Without any jail time, where is the deterrent? We’ve lost two generations to their greed.”

Individual victims and their survivors are to share a US$750-million fund, a key provision not found in other opioid settlements. About 149,000 people made claims in advance and could qualify for shares from the fund.

That amount is unchanged in the new plan, but states will be able to create funds they can use to compensate victims beyond that, if they choose.

Other new provisions include an agreement from Sackler family members that they won’t fight when institutions attempt to take their names off buildings that were funded with the family’s support. And additional company documents are to be made public.

Most of the money is to flow to state and local governments, Native American tribes and some hospitals, with the requirement that it be used to battle an opioid crisis that has been linked to more than 500,000 deaths in the U.S. over the past two decades.

“We’re pleased with the settlement achieved in mediation, under which all of the additional settlement funds will be used for opioid abatement programs, overdose rescue medicines, and victims,” Purdue Pharma said in a statement issued separately from the family’s. “With this mediation result, we continue on track to proceed through the appeals process on an expedited schedule, and we hope to swiftly deliver these resources.”

Kentucky and Oklahoma are not part of the deal because they both reached previous settlements with Purdue.

Purdue, the originator of time-release versions of powerful prescription painkillers, is the highest-profile company out of many that have faced lawsuits over the crisis. It has twice pleaded guilty to criminal charges related to its business practices around OxyContin.

The latest announcement follows another landmark settlement late last week, when drug maker Johnson & Johnson and three distributors finalized a settlement that will send US$26-billion over time to virtually every state and local governments throughout the U.S.

If the latest Purdue deal wins approval, the two settlements will give local communities that have been devastated by opioid addiction a significant boost to help them combat the epidemic.

There are two key differences between the latest Purdue settlement and the previous one struck last year. The Sacklers’ cash contribution has gone up by at least US$1.2-billion, and state attorneys-general and the District of Columbia have now agreed.

The money is to begin flowing after Purdue, which is to be renamed Knoa Pharma, emerges from bankruptcy. It’s not clear when that will be. The last payment under the settlement is not scheduled to be made until 2039.

Last year, the eight states – California, Connecticut, Delaware, Maryland, Oregon, Rhode Island, Vermont and Washington – and D.C. refused to sign on, and then most of them appealed after the deal was approved by the bankruptcy judge.

In December, a U.S. district judge sided with the nine holdouts. The judge, Colleen McMahon, rejected the settlement with a finding that bankruptcy judges lack the authority to grant legal protection to people who don’t themselves file for bankruptcy when some parties disagree.

Purdue appealed that decision, which, if left standing, could have scuttled a common method of reaching settlements in sweeping, complicated lawsuits. The attorneys-general who have signed on are dropping from the main legal battle but are still free to write briefs to tell courts not to allow the protections for people who do not file for bankruptcy themselves.

“No lawsuit, no settlement or any amount of money can ever be enough. The lives Purdue stole, they can never be returned,” California Attorney-General Rob Bonta said in a video news conference Thursday. “It can’t heal the devastating pain families still deal with, but that shouldn’t stop us from ensuring accountability and preventing future deaths.”

The new settlement still requires approval from U.S. Bankruptcy Judge Robert Drain. Appeals related to the previous version of the plan could continue moving through the court system.

Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.